NCT03883087 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
Clinical Trials
4 trialsNCT03883100 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT05495035 2023-03-02
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Unknown
NCT05311943 2022-07-29
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
Shenzhen Second People's Hospital
Phase 3 Unknown